Pharma/virotherapy for oncology
Location: United States
Employees: 11-50
Total raised: $114.5M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Mayo Clini... | ventures.m... |
| - | Southeast ... | semncapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.01.2026 | Series B | $85M | - |
| 20.05.2022 | Series B | $29.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 02.01.2026 | Vyriad Raises Final $25M Series B Tranche | Vyriad, Inc., a Rochester, Minn.-based clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, closed the $25M final tranche to its Series B financing, bringing the total Series B ro... |
| 25.12.2025 | Vyriad Revolutionizes Cancer Care: $85M Fuels "One-Shot" In Vivo CAR T for Multiple Myeloma | Vyriad closes an $85M Series B round. This fuels VV169, its groundbreaking in vivo CAR T-cell therapy. VV169 targets multiple myeloma, delivering a curative genetic payload via a single intravenous injection. This revolutionary approach byp... |
| 23.12.2025 | Vyriad: Final $25 Million Series B Tranche Closed To Advance In Vivo CAR T Candidate Into Clinic | Vyriad, a Rochester, Minnesota-based clinical-stage biotechnology company developing targeted genetic therapies, said it has closed a $25 million final tranche of its Series B financing, bringing the round’s total to $85 million. The compan... |
| 23.12.2025 | The “One Shot” Cure? How Vyriad’s $85M Raise Could Replace Complex CAR-T Labs with a Single Injection | What You Should Know: – Vyriad, Inc. has secured the final $25M of its Series B financing, bringing the total round to $85M led by Mr. Harry Stine of Stine Seed Farms, Inc. – The funding will power the first-in-human trials of VV169, an in ... |
| 12.11.2024 | Учёная вылечила рак с помощью вирусов, которые сама вырастила в лаборатории | Вирусолог Беата Халаши утверждает, что самостоятельное лечение сработало и принесло положительные результаты — но исследователи предупреждают, что такое лечение не стоит повторять. Вирус кори, может атаковать раковые клетки. Источник: Eye O... |
| 18.05.2022 | Vyriad Raises $29.5M in Series B Funding | Vyriad, a Rochester, MN-based clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, raised $29.5M in Series B funding. The round was led by Mr. Harry Stine of Stine Seed Farms, Inc. with... |
| 17.05.2022 | Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur | ROCHESTER, MINNESOTA, UNITED STATES, May 17, 2022 /EINPresswire.com/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by... |
| 17.05.2022 | Minnesota biotech firm Vyriad raises $29.5 million for cancer-fighting viruses | - |
| 05.04.2022 | Oral Vaccine Boosts COVID Immunity | ROCHESTER, MINNESOTA, US, April 5, 2022 /EINPresswire.com/ -- Oral Vaccine Boosts COVID Immunity Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced res... |
| - | Manage your consent preferences Minnesota biotech firm Vyriad raises $29.5 million for cancer-fighting viruses | - |
Show more